The Drug-Induced Respiratory Disease Website and App

XV.ap

XV - Pathology

Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

Last update 17/06/2026

Elastosis is best evidenced using specific elastin staining

Causative drugs

7

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a
I.b
I.g
I.l
I.x
I.ad
II.a
II.b
V.a
V.f
V.m
V.ab
XII.c
XV.a
XV.f
XV.h
XV.i
XV.ap
XVI.a
XVI.b
XVI.m
I.a
I.b
I.d
I.g
I.l
I.x
I.aa
II.a
II.b
III.a
IV.a
V.a
V.b
V.c
V.f
VI.c
IX.f
X.f
XI.b
XI.c
XI.l
XII.a
XII.c
XII.f
XII.g
XII.s
XV.a
XV.c
XV.f
XV.h
XV.i
XV.ak
XV.ap
XVI.ap
XVI.bl
XVII.b
XVII.e
XVII.q
XIX.a
I.b
I.c
I.d
I.e
I.l
I.x
V.b
V.d
V.h
IX.a
X.d
X.j
XI.b
XV.a
XV.o
XV.ap
I.a
I.b
I.d
I.f
I.g
I.u
I.x
I.aq
I.ar
IV.d
V.a
V.b
V.d
V.h
VIII.a
IX.a
IX.ac
X.d
X.j
X.ba
XI.b
XII.ab
XV.c
XV.d
XV.h
XV.o
XV.ap
XV.co
XVI.bx
XIX.f
I.b
I.d
I.f
I.g
I.n
I.v
I.x
II.a
II.e
II.n
III.a
IV.c
IV.m
V.f
VI.b
VIII.av
X.c
XII.a
XV.a
XV.c
XV.d
XV.f
XV.g
XV.z
XV.ak
XV.ap
XV.bv
XVI.w
XVII.m